About Rick Newell

Rick’s is passionate about driving transformational change in healthcare to positively impact the lives of patients and team members by simplifying complexity and embracing innovation. He is Chief Executive Officer at Inflect Health, a nationwide, multispecialty healthcare innovation and investment hub. He also serves as CEO of Healthful, an early-stage care coordination company that helps patients and families navigate their health journeys. He also serves as Chief Transformation Officer for Vituity where he is responsible for the development, implementation, and execution of strategies, programs, and technologies that enhance and transform enterprise-wide healthcare delivery. Rick oversees innovation, startup company investments and partnerships, outpatient medicine, acute psychiatry, neurology, telehealth, payer alignment strategies, consulting, tech partnerships, care coordination, and complex care management.

Rick is a physician executive who is board certified in Clinical Informatics and Emergency Medicine. He obtained his Masters of Public Health in Healthcare Management from Harvard University and completed his Emergency Medicine residency training at Harbor/UCLA Medical Center. He received his medical education at the State University of New York at Buffalo where he was selected as a Junior AOA member. As a second year medical student he co-founded a free health clinic which to this day continues to serve the impoverished communities of Buffalo’s Eastside. He was recognized for his work in this area with the Leonard Tow Humanism in Medicine Award.

Rick served on Vituity’s (formerly CEP America’s) elected board of directors from 2012-2016. From 2014-2016 he served the partnership as a Director of Quality & Performance and oversaw telehealth, CMS quality programs, MedAmerica Qualified Clinical Data Registries (QCDRs), and the administrative fellowship. In 2013 Rick was recognized for his contributions to the Partnership with the Distinguished Service Award.

She has over 20 years of experience in Biotech/Pharma companies. Her passion is to bring healthcare products to patients in a cost-effective and efficient manner. In her role as a Senior Executive, she led Preclinical and Clinical Development teams. She has taken compounds from Discovery to Regulatory Approval and has filed more than 15 Investigational New Drug Applications (IND) in disease areas of neurology, inflammation, virology, pain, and oncology. Two compounds have received New Drug Application (NDA) approvals from the US FDA and Ministry of Health and Welfare, Japan (Kaletra for the treatment of HIV and Horizant (Regnite in Japan) for Restless Legs Syndrome (RLS) and Post Herpetic Neuralgia (PHN)).

Dr. Lal has a doctorate in Pharmaceutical Sciences and Pharmacology from the University of Maryland and a Master’s degree in Pharmacology from the University of Arizona. Dr. Lal has over 60 publications, book chapters, and presentations. She received a Master’s in Management from Stanford University’s MSx (Sloan) Program.